EUVIMEDEUVIMED entdecken
EditorialOpen Access

Targeted cancer therapy: the initial high concentration may slow down the selection for resistance

Mikhail V Blagosklonny

Aging · 2024

DOI: 10.18632/aging.206046 ↗

Kurz gefasst

Editorial in der Zeitschrift Aging, 2024. Verfasst von Mikhail V Blagosklonny. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Antineoplastic Agents, Molecular Targeted Therapy. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance. One should propose that initial drug levels must be maximized, and durations may be minimized, ideally, as portions of preemptive combination of targeted drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmNeoplasmsAntineoplastic AgentsMolecular Targeted TherapyHumans

Stichwörter der Autor:innen

METex14brain metastasescapmatiniblung cancerrapamycinresistance

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.

Zitieren

APA

Blagosklonny, M. V. (2024). Targeted cancer therapy: the initial high concentration may slow down the selection for resistance. Aging. https://doi.org/10.18632/aging.206046

Vancouver

Blagosklonny MV. Targeted cancer therapy: the initial high concentration may slow down the selection for resistance. Aging. 2024. doi:10.18632/aging.206046

BibTeX
@article{Blagosklonny2024,
  author = {Blagosklonny, Mikhail V},
  title = {Targeted cancer therapy: the initial high concentration may slow down the selection for resistance},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.206046}
}
Kostenlos starten →